Skip to content
Peptide Atlas
All peptides

Argireline

Tier 1 · Human trials
Also known as Acetyl hexapeptide-8 · Acetyl hexapeptide-3 · Acetyl glutamyl heptapeptide

Strongest evidence is Tier 1 (human RCTs): Wang 2013 double-blind randomized placebo-controlled study, Blanes-Mira 2002 clinical emulsion work, plus split-face RCTs and comparator trials. However, evidence is decidedly mixed: the strongest positive trial (Wang 2013) was manufacturer-funded, and independent RCTs/evaluations (split-face RCT src-25, Aruan 2023, 2023 independent evaluation src-9) found no significant wrinkle reduction. Mechanistic support is largely in vitro and animal (Blanes-Mira 2002 chromaffin cells, aged-mouse collagen data). A central caveat is that very poor skin penetration casts doubt on the proposed topical mechanism.

Half-life
Not recorded
Routes
Topical
Goals
Skin anti-aging / anti-wrinkle · Cosmetic skin conditioning / hydration · Scar and photodamage remodeling
Cost / mg
Not recorded

How it works

Argireline is a small synthetic peptide designed to mimic part of a natural muscle-signaling protein (SNAP-25). By imitating this fragment, it is proposed to interfere with the machinery nerves use to release the chemical messenger (acetylcholine) that tells facial muscles to contract. The idea is that reducing these contractions softens the repeated creasing that forms expression lines, giving it a marketing reputation as a topical, needle-free alternative to Botox. Importantly, this mechanism is well supported in lab dishes but its relevance to topical cosmetic use is uncertain, because very little of the peptide actually penetrates the skin to reach facial muscles.

Overview

Overview

Argireline (INCI: Acetyl hexapeptide-8; also Acetyl hexapeptide-3, Acetyl glutamyl heptapeptide; CAS 616204-22-9) is a synthetic hexapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 (Ac-EEMQRR-NH2) and a molecular weight of approximately 889 Da. It is a white powder synthesized without excipients, preservatives, or antioxidants, and is highly hydrophilic (LogP ~-6.3).

It was launched in 2001 by Lipotec as the first commercially available peptide ingredient designed to combat expression wrinkles, developed through rational design begun in the early 1990s in the laboratory of Professor Antonio Ferrer-Montiel. The peptide sequence is derived from residues 12-17 of the first SNARE motif of SNAP-25.

Proposed Mechanism

Argireline mimics the N-terminal end of SNAP-25 and is proposed to compete with endogenous SNAP-25 for binding to VAMP2, destabilizing SNARE-complex assembly and inhibiting Ca2+-dependent exocytosis. By interfering with the SNARE complex (SNAP-25/VAMP/syntaxin), it is proposed to blunt acetylcholine release at the neuromuscular junction and thereby reduce the muscle contractions that form expression lines. In vitro it inhibited neurotransmitter release with potency similar to botulinum neurotoxin A, and in permeabilized bovine adrenal chromaffin cells (Blanes-Mira 2002) it dose-dependently inhibited catecholamine release. Analogues Arg2/Arg3 showed enhanced skin permeation, with Arg3 most effective at inhibiting glutamate release.

A key caveat: the precise biological mechanism when applied topically remains incompletely understood, and it is uncertain whether the peptide can reach neuromuscular junctions at all.

Regulatory & Use Context

Argireline is marketed as a bio-safe, needle-free, over-the-counter cosmetic alternative to botulinum toxin ('botox in a bottle') for hyperkinetic expression lines of the forehead, around the eyes, neck, and nasal flare. It functions as a skin-conditioning agent-humectant. It is a cosmetic ingredient, not an approved drug — regulated by the FDA under cosmetic law, with no NDA or IND filed, and it is not equivalent to injected botulinum toxin. As of 2020 the VCRP reported acetyl hexapeptide-8 in 452 cosmetic products. It is also used in formulations for scar treatment, skin rejuvenation, and photodamaged skin, and has been proposed as an adjunct to intramuscular botulinum toxin. Search interest in 'Argireline' and 'Botox in a Bottle' rose substantially in 2022.

Clinical Evidence (Mixed)

  • Blanes-Mira 2002: a 10% oil-in-water emulsion reduced wrinkle depth up to ~30% over 30 days in healthy women.
  • Wang 2013 (double-blind RCT, 60 Chinese subjects, 3:1 argireline:placebo, twice daily 4 weeks): reported 48.9% subjective anti-wrinkle efficacy vs 0% placebo for periorbital lines, with significant objective roughness reductions (p<0.01). This strongest positive trial was manufacturer-funded.
  • Open-label and observational reports: 27% improvement in periorbital lines (10 women, 5% cream, 30 days); up to 17% at 15 days and 30% at 30 days.
  • Independent/less favorable data: a split-face RCT (19 participants) found no significant difference between treated and untreated sides; Aruan 2023 found only small crow's-feet changes, no better than palmitoyl pentapeptide-4; a 2023 independent evaluation found no significant wrinkle reduction; and a blepharospasm pilot (Lungu 2013) did not meet its primary endpoint.

Overall evidence is described as mixed, and the peptide's very poor skin penetration (~0.22% to stratum corneum, ~0.01% to epidermis, >99% failing to reach dermis) is difficult to reconcile with a mechanism requiring action at facial muscles.

Other Findings

In aged mice, twice-daily application for 6 weeks improved skin histology, increased type I collagen (P<0.01) and decreased type III collagen (P<0.05). A 10% gelcream on lesions in 26 patients improved hydration, elasticity, and sebum. A PDO thread system has been proposed as a controlled-release delivery vehicle to reinforce facial harmonization effects.

What the research shows

180 findings extracted from the 29 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 14 human trial findings, 13 human study findings, 2 animal findings, 2 in vitro findings, 2 expert opinion findings and 1 anecdotal finding.

  • human trialAn oil/water emulsion containing 10% Argireline applied to healthy women volunteers reduced wrinkle depth up to 30% upon 30 days treatment1

  • human trialArgireline displays much lower efficacy than botulinum neurotoxin despite similar potency for neurotransmitter inhibition1

  • human trialIn a double-blind, randomized, placebo-controlled study of 60 Chinese subjects, total anti-wrinkle efficacy in the argireline group was 48.9%, compared with 0% in the placebo group3

  • human trialIn objective evaluation using silicone replicas and wrinkle-analysis apparatus, roughness parameters all decreased in the argireline group (p<0.01), while no decrease was obvious in the placebo group (p>0.05)3

  • human trialWrinkle score slightly decreased for the right and left side of the face following four weeks of serum application, but this decrease was not significant5

  • human trialNo statistical significance was seen in wrinkle reduction on the side of face treated with Argireline compared to the side treated without Argireline5

  • human trialThe efficacy of Argireline was found not to be significant5

  • human trialArgireline applied topically twice daily for 4 weeks in a 3:1 randomization versus placebo resulted in 48.9% total anti-wrinkle efficiency in the Argireline group6

Show the remaining 26

  • human trialArgireline notably reduced the depth of periorbital wrinkles in human subjects (P<0.01)6

  • human trialArgireline applied twice daily for 4 weeks showed total anti-wrinkle efficacy of 48.9% in argireline group compared with 0% in placebo group in subjective evaluation7

  • human trialIn objective evaluation, parameters of roughness were all decreased in the argireline group (p < 0.01), while no decrease was obvious in the placebo group (p > 0.05)7

  • human trialWang 2013 randomized placebo-controlled study reported ~49% subjective anti-wrinkle efficacy vs 0% placebo for periorbital lines over 4 weeks10

  • human trialAruan 2023 comparator trial found only small crow's-feet changes with acetyl hexapeptide-3, performing no better than palmitoyl pentapeptide-410

  • human trialLungu 2013 blepharospasm pilot did not meet its primary endpoint10

  • human studyOne prior open-label trial with ten women using 5% argireline cream demonstrated 27% improvement in peri-orbital lines after 30 days measured by silicone replica analysis3

  • human studyIn another study with healthy American women volunteers, argireline solution reduced wrinkle depth up to 17% after 15 days and 30% after 30 days3

  • human studyPeptides have the strongest evidence base for treating photoaging, with most studies achieving Level Ib status in the evidence hierarchy4

  • human studyTopical cosmeceuticals including peptides can effectively treat photodamaged skin4

  • human studyArgireline has been shown to reduce the degree of facial wrinkles7

  • human studyA 10% Argireline-containing oil/water emulsion reduced wrinkle depth up to 30% upon 30 days treatment in healthy women volunteers8

  • human studyArgireline has efficacies up to 48% upon 4 weeks of twice daily treatment12

  • human studyPreclinical and clinical studies indicate that AH-8 may reduce wrinkle depth, improve skin elasticity, and enhance hydration16

  • human studyArgireline-containing cosmetics show confirmed reduction of facial wrinkles18

  • human studyArgireline can reduce the degree of existing facial wrinkles20

  • human studyArgireline demonstrates effectiveness against wrinkle development20

  • human studyArgireline had significant anti-wrinkle effect in Chinese subjects20

  • human studyThe strongest positive trial, published in 2013 by Wang and colleagues, was manufacturer-funded; an independent 2023 evaluation found no significant wrinkle reduction22

  • animalAH-8 has shown beneficial effects in scar remodeling and sebum regulation in some studies16

  • animalArgireline applied twice daily for 6 weeks improved histological structure of skin tissue in aged mice20

  • in vitroBlanes-Mira 2002 in-vitro work showed SNARE-mediated inhibition of neurotransmitter release and a 10% emulsion reduced wrinkle depth up to ~30% over 30 days10

  • in vitroArgireline solution demonstrated dose-dependent anti-proliferation effects in HEK-293, IMR-32, and human primary skin fibroblasts19

  • expert opinionSmall placebo-controlled clinical trials and multiple in vitro and in vivo studies completed; evidence is mixed22

  • expert opinionAcetyl hexapeptide-3 is an effective topical agent for decreasing wrinkles28

  • anecdotalThe cream significantly improved skin values including hydration, elasticity, and sebum27

How it works

Based on 5 human trial findings, 1 human study finding, 6 animal findings, 16 in vitro findings, 12 expert opinion findings and 19 theoretical findings.

  • human trialArgireline is a synthetic hexapeptide with sequence Ac-EEMQRR-NH21

  • human trialArgireline is a synthetic hexapeptide patterned from the N-terminal end of the protein SNAP-253

  • human trialArgireline inhibits vesicle docking by preventing formation of the ternary SNARE complex3

  • human trialArgireline interferes in catecholamine release involved in synaptic vesicle exocytosis3

  • human trialArgireline inhibits the repetitive contraction of the intrinsic muscles of facial expression and thereby reduces hyperkinetic facial lines3

  • human studyArgireline is a hexapeptide (Ac-EEMQRR-NH2) designed to mimic the action of botulinum neurotoxins8

  • animalArgireline applied topically twice daily for 6 weeks in aged mice improved skin tissue morphology6

  • animalArgireline increased the amount of type I collagen fibers in aged mice skin tissue (P<0.01)6

Show the remaining 51

  • animalArgireline decreased type III collagen fibers in aged mice skin tissue (P<0.05)6

  • animalArgireline treatment increased type I collagen fibers in aged mice (P < 0.01)20

  • animalArgireline treatment decreased type III collagen fibers in aged mice (P < 0.05)20

  • animalIn Blanes-Mira et al. (2002) study using permeabilized bovine adrenal chromaffin cells, argireline inhibited catecholamine release with dose-dependent profile through SNARE complex interference23

  • in vitroArgireline significantly inhibited neurotransmitter release with potency similar to BoNT A1

  • in vitroArgireline inhibits neurotransmitter release by interfering with formation and/or stability of the SNARE complex required for Ca2+-dependent exocytosis1

  • in vitroArgireline significantly inhibited neurotransmitter release with potency similar to BoNT A8

  • in vitroArgireline interferes with the formation and/or stability of the SNARE protein complex required for Ca2+-dependent exocytosis8

  • in vitroPermeation studies show ~889 Da, LogP ~-6.3, zwitterionic peptide with <0.2% stratum corneum penetration and ~0.01% reaching epidermis10

  • in vitroOxidation of the methionine residue was detected in Argireline11

  • in vitroArgireline (Arg0) is a synthetic acetyl hexapeptide, patterned after the N-terminal end of the protein Synaptosomal-associated protein 25 (SNAP-25)12

  • in vitroArg0 competes with SNAP-25 for binding with vesicle-associated membrane protein (VAMP), destabilizing formation of SNARE complex and inhibiting neuronal exocytosis12

  • in vitroArg0 inhibits the release of acetylcholine with antiwrinkle activity12

  • in vitroArg0 exists in zwitterionic form which hinders skin permeation12

  • in vitroArg3 was most effective at inhibiting glutamate release from neurons in vitro, followed by Arg1, Arg0 and Arg212

  • in vitroArgireline® prevents formation of skin lines and wrinkles in a very similar way to the botolinum toxin (Botox), inhibiting neurotransmitter release at the neuromuscular junction15

  • in vitroArgireline® acts in similar way as botulinum neurotoxins (Botox®) causing muscle paralysis by inhibiting activity in the presynaptic neuronal exocytosis machinery15

  • in vitroArgireline® is blocking Ca2+ dependent neurotransmitter release (acetylcholine) at neuromuscular junction15

  • in vitroArgireline® is reacting with SNARE complex, consisting of three synaptic proteins SNAP-25, VAMP and syntaxin15

  • in vitroThe methionine residue in Argireline sequence was indicated as oxidation point18

  • expert opinionArgireline is a synthetic hexapeptide5

  • expert opinionArgireline is a synthetic peptide patterned from the N-terminal end of the protein SNAP-257

  • expert opinionBiomimetic peptides represent a growing class of active ingredients in modern cosmeceuticals, designed to mimic the function of the naturally occurring peptides involved in skin homeostasis, repair, and regeneration.9

  • expert opinionPeptides have broad range of biological functions relevant to skincare including modulation of cell proliferation, inflammation, cell migration, melanogenesis, angiogenesis, and protein synthesis11

  • expert opinionThe precise biological mechanisms underlying AH-8 effects—particularly the peptide's ability to inhibit muscle contraction when applied topically—remain incompletely understood16

  • expert opinionAcetyl hexapeptide-8 (Argireline) is a mimetic of botulinum toxin17

  • expert opinionArgireline prevents formation of skin lines and wrinkles by inhibiting neurotransmitter release at the neuromuscular junction, similar to botulinum toxin19

  • expert opinionArgireline (acetyl hexapeptide-8) is a cosmetic peptide proposed to reduce muscle contraction by competing with SNAP-25 in the SNARE complex22

  • expert opinionArgireline was first characterized by Blanes-Mira and colleagues in a 2002 paper as a synthetic mimic of the N-terminal domain of SNAP-2522

  • expert opinionAc-EEMQRR-NH2 mimics the N-terminal end of SNAP-25, competing for SNARE complex assembly and potentially reducing catecholamine release and muscle contraction22

  • expert opinionArgireline and botulinum toxin both target SNARE complex but differ in mechanisms, potencies, and durations of action23

  • expert opinionAcetyl hexapeptide-8, also known as Argireline, is a topical, short-acting, synthetic peptide25

  • theoreticalAcetyl Hexapeptide-8 is defined as the product obtained by the acetylation of hexapeptide-82

  • theoreticalThe sequence for this acetylated peptide is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH22

  • theoreticalAcetyl Hexapeptide-8 has been derived from the N-terminal of the synaptic protein, synaptosomal nerve-associated protein 25 (SNAP-25, 12-17 amino acids)2

  • theoreticalArgireline may theoretically mimic the effects of BoNTA injection by reducing hyperkinetic lines associated with muscles of facial expression3

  • theoreticalArgireline inhibits vesicle docking by preventing formation of the ternary SNARE complex7

  • theoreticalArgireline interferes in catecholamine release7

  • theoreticalAcetyl hexapeptide-8 (AH-8), often referred to as a 'botox-like' peptide, has received considerable attention for its potential to dynamically reduce wrinkles through the modulation of neuromuscular activity.9

  • theoreticalArgireline's sequence mimics the N-terminal of SNAP-25 and is proposed to compete during SNARE-complex assembly, destabilizing the complex and reducing acetylcholine release to slightly blunt the muscle contractions that form expression lines10

  • theoreticalArgireline reduces facial lines and wrinkles by destabilization of the formation of the SNARE complex, thus preventing muscle contraction11

  • theoreticalArgireline® has been derived from N-terminal end of SNAP-25 protein (aa 12–17) with following amino acid sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-NH215

  • theoreticalAcetyl hexapeptide-8 (AH-8) has potential to dynamically reduce wrinkles through the modulation of neuromuscular activity16

  • theoreticalOil-in-water (O/W) and multiple water-in-oil-in-water (W/O/W) emulsions have been explored to enhance delivery of AH-816

  • theoreticalArgireline reinforces the effects of PDO threads17

  • theoreticalArgireline works by inhibiting the release of neurotransmitters in the neuromuscular junction, producing a botox-like effect18

  • theoreticalArgireline is a synthetic peptide patterned from the N-terminal end of the protein SNAP-2520

  • theoreticalArgireline (acetyl hexapeptide-8) is a synthetic hexapeptide with amino acid sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH223

  • theoreticalPeptide sequence derived from N-terminal domain of SNAP-25, specifically residues 12-17 of its first SNARE motif23

  • theoreticalArgireline designed as mimic of N-terminal portion of first SNAP-25 SNARE motif (residues 12-17)23

  • theoreticalArgireline competes with endogenous SNAP-25 for binding to VAMP2, destabilizing SNARE complex formation and inhibiting calcium-dependent exocytosis23

Dosing

Based on 1 human trial finding, 1 anecdotal finding and 1 theoretical finding.

  • human trialArgireline or placebo was applied to peri-orbital wrinkles twice daily for 4 weeks3

  • anecdotalA gelcream containing 10% of acetyl hexapeptide-8 (Argireline®) was applied directly upon lesions followed by light massage27

  • theoreticalCosmetic formulations commonly use roughly 5-10% topically; original studies used a 10% oil-in-water emulsion10

How the body handles it

Based on 1 animal finding, 10 in vitro findings, 3 expert opinion findings and 3 theoretical findings.

  • animalThe transdermal delivery route offered advantages13

  • in vitroArgireline has a molecular weight of 889 Dalton12

  • in vitroArgireline has a LogP value of -6.312

  • in vitroOnly 0.22% of Arg0 total amount permeated through skin and retained within stratum corneum in in vitro human cadaver skin study12

  • in vitro0.01% of Arg0 peptide made it through to the epidermis in in vitro human cadaver skin study12

  • in vitroArg2 and Arg3 peptide analogues demonstrated enhanced human skin permeation in vitro12

  • in vitroAH-8 has hydrophilic nature and relatively large molecular size, facing limited permeability through the lipophilic stratum corneum16

  • in vitroPDO thread is a well-controlled release system for Argireline, allowing its sustained release for 1 h17

Show the remaining 9

  • in vitroPDO thread enjoys capillarity by the peptide, doubling its weight every 24 h when immersed in Argireline17

  • in vitroA 2015 in vitro penetration study found that over 99% of applied argireline failed to reach the dermis, with only 0.01% detected in the viable epidermis22

  • in vitroIn vitro penetration studies show that the vast majority of applied peptide remains in the stratum corneum, with negligible penetration into the viable epidermis and no detectable penetration into the dermis22

  • expert opinionThe ability of AH-8 to reach neuromuscular junctions remains uncertain16

  • expert opinionAH-8's low skin penetration limits its bioavailability and therapeutic potential16

  • expert opinionIt is water-soluble and hydrophilic22

  • theoreticalAcetyl Hexapeptide-8 is soluble in water and has a log P of -6.32

  • theoreticalDue to its hydrophilic nature and relatively large molecular size, AH-8 faces limited permeability through the lipophilic stratum corneum, making effective dermal delivery challenging.9

  • theoreticalNo established human pharmacokinetic half-life; applied topically with negligible systemic absorption10

Safety and side effects

Based on 2 human trial findings, 4 human study findings, 3 animal findings, 4 in vitro findings, 13 expert opinion findings and 1 anecdotal finding.

  • human trialThere were no significant adverse events, allergic reactions, or skin irritations following four weeks of Argireline serum application5

  • human trialArgireline presented with low toxicity5

  • human studyArgireline was safe and well tolerated in past studies20

  • human studyAcetyl hexapeptide-8 (argireline) injections in the forehead and temples resulted in erythema, nodules, and abscesses at injection sites after one week in a 45-year-old woman26

  • human studyInfection with mycobacterium was confirmed via microbiological culture of pus specimens following argireline injection26

  • human studyClarithromycin 500 mg twice daily and moxifloxacin 400 mg once daily were administered for 5 months with gradual subsidence of lesions26

  • animalArgireline did not exhibit in vivo oral toxicity nor primary irritation at high doses1

  • animalArgireline did not exhibit in vivo oral toxicity nor primary irritation at high doses8

Show the remaining 19

  • animalArgireline was found to be a safe compound in comparison to doxorubicin13

  • in vitroPrevious reports on possible Argireline transformations in cosmetic formulations have not confirmed deacetylation11

  • in vitroSignificant cytotoxicity of argireline® solution was observed under 18 to 10 000 fold higher concentrations (depending on cells that were examined) in comparison to doxorubicin15

  • in vitroDose-dependent argireline® anti-proliferation effects were observed in human embryonic kidney HEK-293 cell line, human neuroblastoma IMR-32 cell line, and human primary skin fibroblasts15

  • in vitroArgireline showed significant cytotoxicity at 18 to 10,000 fold higher concentrations compared to doxorubicin depending on cell type examined19

  • expert opinionThe biological activity of oxidized Argireline is not known11

  • expert opinionArg0 has acute toxicity of ≥2000 mg/kg (compared to 20 ng/kg for Botox)12

  • expert opinionArgireline is safer than Botox12

  • expert opinionArgireline is believed to be relatively safe14

  • expert opinionArgireline® does not require under skin muscle injections and it is believed to be relatively safe15

  • expert opinionAcetyl Hexapeptide-8 Amide is safe in cosmetics at concentrations up to 0.005%21

  • expert opinionAvailable data are insufficient for evaluating safety at higher concentrations above 0.005%21

  • expert opinionA no-observed-adverse-effect-level (NOAEL) for type I and type III collagen synthesis would be needed in order to evaluate the safety of Acetyl Hexapeptide-8 Amide in cosmetic products at concentrations > 0.005%21

  • expert opinionAs of April 2026, argireline (acetyl hexapeptide-8) is a cosmetic ingredient regulated by the FDA under cosmetic law, not as a drug. No NDA or IND has been filed for argireline. It is not FDA-approved for any therapeutic indication22

  • expert opinionAcetyl Hexapeptide-8 Amide is safe in cosmetics at concentrations up to 0.005%24

  • expert opinionAvailable data are insufficient to determine safety of Acetyl Hexapeptide-8 Amide at concentrations greater than 0.005% in cosmetic formulations24

  • expert opinionInfection following argireline injection is easily misdiagnosed as a common bacterial infection26

  • expert opinionStandardized cosmetic procedures can prevent infection with mycobacterium following argireline injection26

  • anecdotalNo allergic reactions were documented during the treatment period27

What people use it for

Based on 2 human trial findings, 2 human study findings, 20 expert opinion findings, 2 anecdotal findings and 1 theoretical finding.

  • human trialArgireline is not deemed to be an alternative treatment to botulinum toxin based on efficacy findings5

  • human trialArgireline had a significant anti-wrinkle effect in Chinese subjects7

  • human studyArgireline is a topical cosmeceutical used to treat photodamaged skin4

  • human studyArgireline is a non-toxic antiwrinkle peptide that emulates the action of botulinum neurotoxins8

  • expert opinionAcetyl Hexapeptide-8 functions as a skin-conditioning agent-humectant2

  • expert opinionAcetyl Hexapeptide-8 Amide functions as a skin-conditioning agent-miscellaneous2

  • expert opinionArgireline was previously deemed to be a biosafe alternative to botulinum neurotoxin5

  • expert opinionAH-8 is widely used in topical formulations intended for anti-aging effects, scar treatment, and skin rejuvenation.9

Show the remaining 19

  • expert opinionArgireline is a cosmetic ingredient, not an approved drug, and not equivalent to injected botulinum toxin10

  • expert opinionArgireline is a bio-safe cosmetic alternative to botulinum toxin11

  • expert opinionArgireline does not require under skin muscle injections14

  • expert opinionArgireline® actively peptide inhibits skin muscle contraction, especially in the forehead, neck, nasal flare and around the eyes15

  • expert opinionAH-8 is widely used in topical formulations intended for anti-aging effects, scar treatment, and skin rejuvenation16

  • expert opinionArgireline is used as a safe needle-free alternative to botox treatment18

  • expert opinionArgireline is a short chain peptide used as active ingredient in dermal ointment and creams19

  • expert opinionArgireline does not require under skin muscle injections19

  • expert opinionReported use frequency of Acetyl Hexapeptide-8 Amide in cosmetics has decreased by more than 100 uses21

  • expert opinionArgireline launched in 2001 by Lipotec as first commercially available peptide ingredient designed to combat expression wrinkles through neurotransmitter modulation23

  • expert opinionAcetyl Hexapeptide-8 Amide (synonymous with Argireline) functions as a skin conditioning agent in cosmetics24

  • expert opinionArgireline has antiwrinkle effects25

  • expert opinionArgireline has emerged as a more accessible alternative to botulinum neurotoxin25

  • expert opinionThe increasing interest in acetyl hexapeptide-8 may be due to its cost-effectiveness and use as a botulinum neurotoxin alternative25

  • expert opinionArgireline has over-the-counter availability and ease of self-application25

  • expert opinionAcetyl hexapeptide-3 can be used as an adjunct to intramuscular botulinum neurotoxin, which may reduce the number of injections needed28

  • anecdotalThe cream improved self-image expectation of patients27

  • anecdotalTopical administration of the cosmeceutical cream is a safe and effective alternative to invasive procedures for skin disorders such as cancer, surgical scars, hidradenitis, and aging wrinkles27

  • theoreticalPDO thread system with Argireline is an intelligent bioactive system useful in facial harmonization17

Other findings

Based on 1 in vitro finding, 4 expert opinion findings, 3 anecdotal findings and 5 theoretical findings.

  • in vitroArgireline and its oxidized form are present in several different cosmetics18

  • expert opinionReversed-phase high performance liquid chromatography coupled with mass spectrometry (LC-MS) is the method of choice in bioactive peptide analysis11

  • expert opinionThe molecular weight is approximately 889 daltons22

  • expert opinionArgireline was developed through rational design initiated in early 1990s at laboratory of Professor Antonio Ferrer-Montiel23

  • expert opinionAs of 2020, VCRP reported acetyl hexapeptide-8 in 452 cosmetic products23

  • anecdotalThe terms 'Argireline' and 'Botox in a Bottle' both had substantial increases in search volume in 202225

  • anecdotalArgireline search volume is drastically increasing25

  • anecdotalArgireline was less searched than Botox, which had a stable, up-trending search volume over the past decade25

Show the remaining 5

  • theoreticalAcetyl Hexapeptide-8 is a white powder with a molecular weight of 889.0 Da2

  • theoreticalAcetyl Hexapeptide-8 is completely synthesized in the laboratory and no excipients, preservatives, or antioxidants are used during the manufacturing process2

  • theoreticalArgireline has the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH211

  • theoreticalArgireline® (acetyl hexapeptide-3) is a synthetic anti-aging peptide produced by Lipotec LTD. company15

  • theoreticalMolecular weight of argireline is 888.96 g/mol23

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Studies disagree on whether topical argireline actually reduces wrinkles

Manufacturer-associated trials report ~48.9% subjective anti-wrinkle efficacy versus 0% placebo (The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study., The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects, The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects.) and 17-30% wrinkle depth reduction (A synthetic hexapeptide (Argireline) with antiwrinkle activity, The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects, A synthetic hexapeptide (Argireline) with antiwrinkle activity.), while an independent split-face RCT found no significant effect (Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the VisiaComplexion Analysis camera system for objective skin analysis.), the Aruan 2023 comparator found only small changes no better than another peptide (Argireline: Mechanism, Status, Dose Reference & Half-Life), and a 2023 independent evaluation found no significant wrinkle reduction (Superpower). Evidence is described overall as mixed.

Limited evidence

The strongest positive trial was manufacturer-funded

Superpower notes the strongest positive trial (Wang 2013, also reported in Argireline: Mechanism, Status, Dose Reference & Half-Life, The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study., The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects, The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects.) was manufacturer-funded, whereas independent evaluations were less favorable.

Limited evidence

Very poor skin penetration casts doubt on the proposed mechanism

In vitro studies show only ~0.22% reaches the stratum corneum and ~0.01% the epidermis with negligible/no dermal penetration (Argireline: Mechanism, Status, Dose Reference & Half-Life, Superpower, Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification | Scientific Reports). Sources note AH-8's ability to reach neuromuscular junctions remains uncertain and its low penetration limits bioavailability and therapeutic potential (Acetyl Hexapeptide-8 in Cosmeceuticals—A Review of Skin Permeability and Efficacy, Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy.), which is difficult to reconcile with a mechanism requiring action at facial muscles.

Contested

Cosmetic products and studies use concentrations far above the level a cosmetics safety panel found data to support

The Cosmetic Ingredient Review Expert Panel, an industry safety-review body rather than a government regulator, concluded that Acetyl Hexapeptide-8 Amide is safe in cosmetics only at concentrations up to 0.005%, and that the available data were insufficient to judge safety at higher concentrations — a gap in evidence, not a finding that higher levels are unsafe (Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in ..., Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics.). Yet cosmetic formulations are commonly described as using roughly 5-10% (Argireline: Mechanism, Status, Dose Reference & Half-Life), and the trials themselves worked well above 0.005%: a 10% oil-in-water emulsion in A synthetic hexapeptide (Argireline) with antiwrinkle activity, a 5% cream and other preparations noted in The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects, and a 10% gelcream in Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8.

Limited evidence

In vitro cytotoxicity was observed, though only at very high concentrations

Argireline showed dose-dependent anti-proliferation and cytotoxicity in HEK-293, IMR-32 and skin fibroblast cell lines, but only at 18 to 10,000 fold higher concentrations than doxorubicin (The study of cellular cytotoxicity of argireline® — an anti-aging peptide*, The study of cellular cytotoxicity of argireline - an anti-aging peptide.). Sources still characterize it as relatively safe (The study of cellular cytotoxicity of argireline® — an anti-aging peptide*, The study of cellular cytotoxicity of argireline - an anti-aging peptide., Investigating the effects of Argireline in a skin serum containing hyaluronic ...).

Single source

Serious infection reported only from off-label injection, not topical use

A single case report describes mycobacterial infection with abscesses after forehead/temple injections of argireline in a 45-year-old woman (infection after facial injection of argireline: A case report.); argireline is intended for topical use, and this involved an off-label injection route.

Single source

Aged-mouse collagen data come from a limited set of studies

Claims that argireline increases type I and decreases type III collagen fibers and improves skin histology derive from animal (aged mice) studies reported in The anti-wrinkle efficacy of Argireline. and The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. only.

Using it with other compounds

Check a stack
  • MatrixylComplementary

    May be complementary

    These attack expression lines from two different angles: Argireline relaxes the muscle movement that creates dynamic wrinkles, while Matrixyl (Pal-KTTKS) stimulates fibroblasts to build type I/III collagen and matrix, addressing the structural/static component of aging skin. Combining a muscle-signaling peptide with a collagen-building matrikine is a classic complementary topical pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the collagen_synthesis shared dimension and complementary relationship type. Argireline's mechanism explicitly includes 'Type I / type III collagen synthesis (animal data)' in its pathways and carries the collagen_synthesis tag. Matrixyl's mechanism prominently features 'Stimulation of collagen types I, III, and IV synthesis' as a primary effect and also carries the collagen_synthesis tag. The proposed explanation accurately reflects their distinct mechanistic approaches: Argireline targets SNARE complex components to inhibit acetylcholine release at the neuromuscular junction (reducing dynamic wrinkles via muscle relaxation), while Matrixyl acts through matrikine signaling and TGF-beta pathways to directly stimulate fibroblast collagen production (addressing static/structural aging). These represent genuinely different biological mechanisms converging on collagen synthesis, making them mechanistically complementary rather than redundant. The explanation's characterization of their combined action—muscle relaxation plus matrix building—is directly supported by the provided mechanism descriptions.

    Shares collagen synthesis

  • SNAP-8Same mechanism

    Worth caution

    SNAP-8 is essentially an extended version of Argireline — both are synthetic mimics of the SNAP-25 protein that competitively interfere with SNARE complex assembly to reduce acetylcholine release at facial muscles. Because they hit the exact same target by the same mechanism, layering both is redundant rather than additive; you are paying for two peptides doing one job. Choose one rather than stacking.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the proposed relationship. Peptide A (Argireline) and Peptide B (SNAP-8) both: (1) target SNAP-25 and the SNARE complex, (2) operate via the same pathway (SNARE-mediated exocytosis and acetylcholine release at the neuromuscular junction), (3) share the approved tag 'acetylcholine_pathway', and (4) are explicitly described as synthetic mimics designed to interfere with the same natural protein machinery. The mechanism descriptions confirm they act on identical molecular targets through identical mechanisms. The explanation that SNAP-8 is 'an extended version of Argireline' and both competitively interfere with SNARE assembly to reduce acetylcholine release is directly supported by the provided mechanism material.

    Shares acetylcholine pathway

  • Palmitoyl Tripeptide-1Complementary

    May be complementary

    Palmitoyl Tripeptide-1 (Pal-GHK) drives collagen, elastin and matrix synthesis in the dermis, complementing Argireline's relaxation of the facial muscles that fold the skin. One works on the underlying structural scaffold while the other reduces the repetitive creasing, so together they can address both static and dynamic contributors to lines.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms support collagen_synthesis as a shared dimension. Argireline's mechanism explicitly includes 'Type I / type III collagen synthesis (animal data)' in its pathways and carries the 'collagen_synthesis' approved tag. Palmitoyl Tripeptide-1's mechanism prominently features 'Stimulation of collagen types I and III synthesis' and multiple pathway activations (TGF-β, Smad-dependent transcription of COL1A1/COL3A1) with the 'collagen_synthesis' approved tag. The proposed complementary relationship is justified: Argireline targets neuromuscular acetylcholine release to reduce dynamic wrinkles, while Palmitoyl Tripeptide-1 stimulates dermal matrix synthesis including collagen. Both contribute to collagen synthesis through different mechanisms (neurological vs. fibroblast signaling), making them mechanistically complementary for addressing both dynamic and static skin aging features as claimed.

    Shares collagen synthesis

  • SYN-AKEComplementary

    May be complementary

    Both aim to relax hyperkinetic expression muscles to soften wrinkles, but by different molecular steps: Argireline blocks the SNARE machinery that releases acetylcholine, while SYN-AKE blocks the postsynaptic nicotinic acetylcholine receptor that receives the signal. Hitting the same neuromuscular pathway at two different points can be complementary for topical line-smoothing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly target the acetylcholine pathway at different molecular steps: Argireline inhibits presynaptic acetylcholine release via SNARE complex interference, while SYN-AKE blocks postsynaptic nicotinic acetylcholine receptor signaling. Both are documented to reduce wrinkle appearance through muscle relaxation. The proposed relationship as 'complementary' is justified—they act on the same neuromuscular pathway (acetylcholine_pathway, a shared approved tag) but at distinct sequential points (presynaptic vs. postsynaptic), which is a valid definition of complementary mechanism. The explanation accurately reflects the mechanism descriptions provided.

    Shares acetylcholine pathway

  • LeuphasylComplementary

    May be complementary

    Leuphasyl reduces acetylcholine release through an enkephalin/opioid presynaptic route (Gi-coupled calcium-channel inhibition), whereas Argireline blocks SNARE-mediated vesicle fusion — two different upstream brakes on the same neuromuscular junction. Vendor and formulation sources specifically report an additive/synergistic wrinkle effect when the two are combined topically.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly target the acetylcholine pathway at the neuromuscular junction but via distinct upstream mechanisms: Argireline directly inhibits SNARE-complex-mediated vesicle fusion (blocking the final exocytosis step), while Leuphasyl reduces calcium influx via enkephalin/opioid receptor signaling and voltage-gated calcium channel inhibition (blocking an earlier step in the release cascade). These are mechanistically complementary interventions on the same pathway. Both peptides are explicitly tagged with 'acetylcholine_pathway,' and the mechanism descriptions support independent but convergent effects on acetylcholine release. The proposed explanation aligns with the provided mechanisms, and the vendor-reported additive/synergistic effect is consistent with dual inhibition at different points in the same signaling cascade.

    Shares acetylcholine pathway

Safety and side effects

Safety Profile

Argireline is generally characterized as relatively safe for topical cosmetic use and does not require under-skin muscle injections. In animal studies it did not exhibit in vivo oral toxicity or primary irritation at high doses, and its reported acute toxicity is ≥2000 mg/kg (compared with ~20 ng/kg for Botox), leading sources to describe it as safer than botulinum toxin. In a split-face serum study there were no significant adverse events, allergic reactions, or skin irritations after four weeks, with low reported toxicity.

Regulatory Safe Limit vs. Formulation Concentrations

An important tension exists: the CIR panel concluded Acetyl Hexapeptide-8 Amide is safe in cosmetics only up to 0.005%, with available data insufficient to evaluate safety above that concentration (a NOAEL for type I and type III collagen synthesis would be needed). However, common cosmetic formulations and the clinical studies used roughly 5-10% — far above the panel's evaluated safe limit.

In Vitro Cytotoxicity

Argireline showed dose-dependent anti-proliferation and cytotoxicity in HEK-293, IMR-32, and human primary skin fibroblast cell lines, but only at concentrations 18 to 10,000 fold higher than doxorubicin depending on cell type. Sources still characterize it as relatively safe.

Serious Case Report (Off-Label Injection)

A single case report describes a 45-year-old woman who received off-label injections of acetyl hexapeptide-8 into the forehead and temples and developed erythema, nodules, and abscesses within one week, with culture-confirmed mycobacterial infection requiring 5 months of clarithromycin and moxifloxacin. This adverse outcome involved an injection route, not intended topical use.

Chemical Stability Note

Methionine oxidation of argireline has been detected in cosmetic formulations (deacetylation was not confirmed); the biological activity of oxidized argireline is not known.

Reconstitution and handling

Preparation & Formulation

Argireline is supplied as a white synthetic powder (CAS 616204-22-9) without excipients, preservatives, or antioxidants. It is water-soluble/hydrophilic (LogP ~-6.3), which favors aqueous cosmetic vehicles but, combined with its ~889 Da size and zwitterionic form, limits penetration through the lipophilic stratum corneum.

Typical Topical Concentrations

  • Cosmetic formulations commonly use roughly 5-10% topically.
  • The original studies used a 10% oil-in-water emulsion.
  • Note that this greatly exceeds the CIR-evaluated safe concentration of 0.005% (see safety section).

Dosing Regimen (as studied)

  • In the pivotal RCT (Wang 2013), argireline or placebo was applied to periorbital wrinkles twice daily for 4 weeks.
  • Other reported regimens include 5% cream and solutions applied over 15-30 days.

Delivery Considerations

Because of poor skin permeation (in vitro: ~0.22% reaching the stratum corneum, ~0.01% the viable epidermis, and >99% failing to reach the dermis), delivery strategies have been explored. Analogues Arg2 and Arg3 demonstrated enhanced human skin permeation in vitro, and a PDO thread system was reported to act as a controlled-release vehicle — providing sustained release for 1 hour and doubling in weight every 24 hours when immersed in argireline solution.

Route

Argireline is intended for topical cosmetic application. It is not an approved injectable, and off-label injection has been associated with serious infection (see safety section).

Sources

Ordered by evidence quality — the strongest first.

  1. A synthetic hexapeptide (Argireline) with antiwrinkle activity(opens in a new tab)
    Tier 1Web · onlinelibrary.wiley.com
  2. Safety Assessment of Acetyl Hexapeptide-8 and ...(opens in a new tab)
    Tier 1Web · cir-safety.org
  3. The Anti-Wrinkle Efficacy of Argireline, a Synthetic Hexapeptide, in Chinese Subjects(opens in a new tab)
    Tier 1Web · dermagist.com
  4. Cosmeceuticals in photoaging: A review.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  5. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the VisiaComplexion Analysis camera system for objective skin analysis.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  6. The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2013
  7. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2013
  8. A synthetic hexapeptide (Argireline) with antiwrinkle activity.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  9. Acetyl Hexapeptide-8 in Cosmeceuticals—A Review of Skin Permeability and Efficacy(opens in a new tab)
    Tier 2Web · mdpi.com
  10. Argireline: Mechanism, Status, Dose Reference & Half-Life(opens in a new tab)
    Tier 2Web · peptidestat.com
  11. Chemical and biological properties of anti-wrinkle peptide Argireline(opens in a new tab)
    Tier 2Web · aestheticcosmetology.com
  12. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification | Scientific Reports(opens in a new tab)
    Tier 2Web · nature.com
  13. Investigating the effects of Argireline in a skin serum containing hyaluronic ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  14. The study of cellular cytotoxicity of argireline - an anti-aging peptide.(opens in a new tab)
    Tier 2Web · researchgate.net
  15. The study of cellular cytotoxicity of argireline® — an anti-aging peptide*(opens in a new tab)
    Tier 2Web · frontierspartnerships.org
  16. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  17. Polydioxanone Bioactive Sutures-Acetyl Hexapeptide-8 (Argireline): An Intelligent System for Controlled Release in Facial Harmonization.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  18. Argireline: Needle-Free Botox as Analytical Challenge.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  19. The study of cellular cytotoxicity of argireline - an anti-aging peptide.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2014
  20. The anti-wrinkle efficacy of Argireline.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2013
  21. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in ...(opens in a new tab)
    Tier 3Web · cir-safety.org
  22. Superpower(opens in a new tab)
    Tier 3Web · superpower.com
  23. Argireline (Acetyl Hexapeptide-8): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 3Web · peptideinsight.com · 2026
  24. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  25. Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  26. infection after facial injection of argireline: A case report.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  27. Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  28. Facial rejuvenation: combining cosmeceuticals with cosmetic procedures.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2014
  29. Investigating the effects of Argireline in a skin serum containing hyaluronic ...(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov